预约演示
更新于：2025-08-12
Utidelone
优替德隆
更新于：2025-08-12
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C27H41NO5S |
InChIKeyXOZIUKBZLSUILX-GIQCAXHBSA-N |
CAS号189453-10-9 |
关联
53
项与 优替德隆 相关的临床试验NCT07044349
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT06973421
Preliminary Phase II Clinical Study on the Efficacy and Safety of the Combination of Utidelone Capsules and Fruquintinib Capsules in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
NCT07021261
A Multicenter, Open-Label, Randomized, Phase III Study Comparing UTD2 Combined With Capecitabine to Capecitabine Monotherapy as Adjuvant Therapy for Triple-Negative Breast Cancer Patients Who Did Not Achieve Pathological Complete Response
100 项与 优替德隆 相关的临床结果
登录后查看更多信息
100 项与 优替德隆 相关的转化医学
登录后查看更多信息
100 项与 优替德隆 相关的专利（医药）
登录后查看更多信息
271
项与 优替德隆 相关的文献（医药）2025-06-01iScience
Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death
Article
作者: Wu, Chuntao ; Dong, Hanguang ; Zhou, Jingyi ; Zhang, Kangnan ; Liu, Chuan ; Gu, Haitao ; Xu, Ling ; Long, Jiang ; Wang, Fan ; Li, Qi
Utidelone (UTD1), a microtubule-stabilizing agent, shows antitumor effects in solid tumors but its role in pancreatic ductal adenocarcinoma (PDAC) is unclear. We assessed UTD1 alone and with gemcitabine (GEM) using in vitro assays (CCK8, colony formation, apoptosis, and cell cycle) and in vivo xenograft and immunocompetent KPC models. UTD1 suppressed cell proliferation, induced apoptosis, and caused G2/M arrest dose-dependently. The UTD1+GEM combination enhanced antitumor efficacy in vitro and in vivo. Mechanistically, UTD1 + GEM increased immunogenic cell death (ICD) markers. In KPC models, the combination improved survival, reduced tumors, and increased CD4+/CD8+ T cell infiltration and PD-L1 expression. Clinically, UTD1 + GEM demonstrated good tolerability, high disease control rates, and favorable immunophenotypic changes. These findings suggest UTD1 triggers ICD, enhancing immune recognition of tumor cells, and highlight its potential as a therapeutic strategy for PDAC.
2025-02-28Clinical Psychopharmacology and Neuroscience
Effects of Epothilone D on Social Defeat Stress-induced Changes in Microtubule-related and Endoplasmic Reticulum Stress Protein Expression
Article
作者: Oh, Jung-Mi ; Li, Ling ; Chun, Sungkun ; Le, Thi-Hung ; Rami, Fatima Zahra ; Chung, Young-Chul
Objective:
Epothilone D (EpoD), microtubule (MT) stabilizing agent, demonstrated promising results in the animal models of Alzheimer's disease, Parkinson's disease and schizophrenia. The present study sought to investigate preventive effects of EpoD on altered changes of MT related proteins and endoplasmic reticulum (ER) stress proteins induced by social defeat stress (SDS).
Methods:
We measured protein expression levels of α-tubulin and its post-translational modifications, MT-associated protein 2, stathmin1 and 2 with their phosphorylated forms, and ER stress markers, 78-kDa glucose-regulated protein (GRP-78) and CCAAT/enhancer binding protein (C/EBP)-homologous protein (CHOP) in the prefrontal cortex (PFC) and hippocampus (HIP) of C57BL/6J strain mice treated with EpoD (2 mg/kg) or its vehicle, dimethylsulfoxide (DMSO), and exposed to SDS.
Results:
We observed lower levels of acetylated α-tubulin, MAP2, p-STMN (Ser16), and GRP-78 in the PFC of the EpoD-Con group when compared to the DMSO-Con group. On the other hand, in the HIP, there were significantly higher levels of tyrosinated α-tubulin and GRP-78 in the EpoD-Defeat group compared to the DMSO-Defeat group. Furthermore, the level of MAP2 in the HIP was found to be lower in the EpoD-Con group compared to the DMSO-Con group.
Conclusion:
Our results suggest that EpoD exhibits a dual impact, manifesting both beneficial and detrimental effects on the aberrant changes of MT-related proteins and ER stress proteins induced by SDS, depending on the brain regions. These findings underscore the complexity of EpoD's effects, necessitating further exploration to understand its intricate mechanisms in cellular pathways linked to SDS.
2025-01-01ANTI-CANCER DRUGS
Utidelone plus pembrolizumab as the fourth-line combination treatment in non-small cell lung cancer with EGFR mutation: a case report
Article
作者: Fang, Henghu ; Zhu, Qi ; Han, Qing ; Wu, Shanshan ; Guan, Gaowa ; Yang, Wei ; Li, Jingjiao ; Wen, Juyi ; Zhao, Rugang ; Zheng, Wei ; Lu, Zejun
Utidelone is an ebomycin derivative chemotherapeutic drug, which can promote tubulin polymerization and stabilize microtubule structure, so as to induce apoptosis. The drug is an innovative drug independently developed by China with independent intellectual property rights. Phase II clinical trials for advanced breast cancer are being approved by National Medical Products Administration for the treatment of advanced breast cancer. However, there is no report on the application in non-small cell lung cancer (NSCLC) patients with the epidermal growth factor receptor (EGFR) mutation. This case is a patient with EGFR mutant stage IV NSCLC who has progressed after third-line targeted therapy. The fourth line was treated with utidelone combined with pabolizumab. The patient had progressed after targeted therapy with oxitinib, ametinib, and vometinib. Due to the patient’s physical reasons, the traditional platinum drugs were not suitable, so the patient was treated with utidelone combined with pabolizumab. The curative effect was evaluated as SD after two cycles and progesterone receptor after four cycles. At present, it is still in the maintenance of reduction of utidelone combined with pabolizumab, and the tumor continues to shrink. Although peripheral neurotoxicity occurred during treatment, it improved after symptomatic treatment. The treatment of EGFR mutant stage IV NSCLC with utidelone combined with pabolizumab has good effect and mild adverse reactions.
100 项与 优替德隆 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 复发性乳腺癌 | 中国 | 2021-03-11 | |
| 转移性乳腺癌 | 中国 | 2021-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃食管交界处癌 | 临床3期 | 中国 | 2025-07-16 | |
| 胃食管交界处腺癌 | 临床3期 | - | 2025-05-01 | |
| 胃腺癌 | 临床3期 | - | 2025-05-01 | |
| 局部晚期非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
| 转移性非小细胞肺癌 | 临床3期 | 中国 | 2023-05-12 | |
| HER2 阴性乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
| 局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
| 局部晚期乳腺癌 | 临床3期 | 中国 | 2022-03-01 | |
| 复发性铂耐药性卵巢癌 | 临床2期 | - | 2025-09-01 | |
| 输卵管癌 | 临床2期 | 中国 | 2025-07-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 转移性HER2阴性乳腺癌 HER2/Neu Negative | 47 | 鏇顧鹹構襯壓壓積糧簾(獵築築窪遞顧襯鑰鑰築) = 鬱積窪鬱鏇衊鬱簾鏇構 憲築遞鬱獵憲壓觸簾鏇 (獵膚艱蓋願願廠築糧遞, 28.3 ~ 57.8) 更多 | 积极 | 2025-06-26 | ||
临床1/2期 | 31 | Utidelone capsule (UTD2) 50 mg/m^2/d-5day | 構膚蓋鬱鬱糧積艱範構(網醖艱齋艱範鏇襯範衊) = the most common ≥ Grade 3 AE was diarrhea appeared at 75 mg/m^2/d-7day, but recovered within 24 hours after supportive treatment 窪夢夢構鹹範醖衊鹹觸 (鬱鹹窪觸鏇製願築鏇醖 ) 更多 | 积极 | 2025-05-30 | ||
Utidelone capsule (UTD2) 75 mg/m^2/d-5day | |||||||
临床2期 | 47 | Utidelone + Sintilimab + Oxaliplatin | 觸範齋夢遞顧製築壓衊(顧壓艱餘觸選構餘憲範) = 膚衊網築蓋構膚構積遞 醖壓鏇襯糧襯蓋廠餘選 (願憲積繭衊窪醖鏇積觸 ) 更多 | 积极 | 2025-05-30 | ||
Utidelone + Tislelizumab + Capecitabine | 觸範齋夢遞顧製築壓衊(顧壓艱餘觸選構餘憲範) = 壓艱餘鹹艱網觸窪簾積 醖壓鏇襯糧襯蓋廠餘選 (願憲積繭衊窪醖鏇積觸 ) 更多 | ||||||
临床2期 | 25 | 構觸壓鹽蓋鹹鬱齋窪製(壓獵簾繭選鑰蓋廠憲鹹) = 鑰鏇製範廠觸遞網簾鹹 鬱夢範鹹鹹壓憲膚壓衊 (鹹餘顧鏇廠築齋壓壓遞 ) 更多 | 积极 | 2025-05-14 | |||
临床1期 | 5 | 構選憲膚憲壓淵繭齋衊(艱範艱衊鬱築廠積糧構) = 鑰範襯夢夢範齋憲廠夢 憲獵遞觸鹽選顧觸餘齋 (觸襯鏇繭壓鹹糧網製築 ) | 积极 | 2024-05-24 | |||
構選憲膚憲壓淵繭齋衊(艱範艱衊鬱築廠積糧構) = 選鬱衊餘膚糧選積構構 憲獵遞觸鹽選顧觸餘齋 (觸襯鏇繭壓鹹糧網製築 ) 更多 | |||||||
临床2期 | 脑转移瘤 HER2-negative | 46 | Utidelone plus bevacizumab | 蓋製積醖襯壓網鹽膚糧(網鹹糧醖繭製醖餘窪壓) = 築憲壓齋願鬱鏇鏇齋蓋 遞鹹廠觸鏇窪齋構選餘 (壓築鹽廠願夢構築鬱淵, 28.9% ~ 58.9) 更多 | 积极 | 2024-05-24 | |
临床2期 | 79 | Utidelone plus sintilimab and oxaliplatin | 齋醖窪鹽構鹽鹹選鹽願(衊遞鹹糧餘夢網選鬱鬱) = Grade 3/4 TRAEs occurred in 27.8% of pts in stage I, and included anemia (13.9%), peripheral neuropathy (11.4%) and neutropenia (7.6%). No treatment-related deaths occurred. Gastric cancer was chosen as the expansion cohort indication. As of February 1st2024, 14 eligible pts with GC with a median age of 57 years (range, 41-69) were enrolled. The median follow-up was 5.5 months (range, 1.0-9.7) and the longest duration of response was 8.0 months. A total of 8 PRs and 3 SDs were achieved in the 11 pts evaluable for efficacy, and 6 pts including the 3 with SD were still receiving treatment. Grade 3/4 TRAEs occurred in 28.6% of pts including diarrhea (14.3%), fatigue (14.3%), neutropenia (14.3%), and vomiting (7.1%). Other AEs were all Grade 1 or 2, with no treatment-related deaths. 顧鏇願窪鏇鹽壓鑰膚淵 (鹹襯艱構簾願鏇構餘獵 ) 更多 | 积极 | 2024-05-24 | ||
临床2期 | 26 | Utideloneutidelone | 願構淵遞夢簾顧範淵遞(觸淵廠選憲簾齋網鬱顧) = 積願廠醖構憲顧鏇觸壓 製築鏇廠餘窪窪選糧鬱 (蓋窪積憲鑰醖鹽襯積衊, 4.4 ~ 34.9) 更多 | 积极 | 2024-04-01 | ||
願構淵遞夢簾顧範淵遞(觸淵廠選憲簾齋網鬱顧) = 鏇廠範襯獵蓋顧膚蓋襯 製築鏇廠餘窪窪選糧鬱 (蓋窪積憲鑰醖鹽襯積衊, 5.4 ~ 41.9) 更多 | |||||||
N/A | 50 | 顧顧蓋網繭衊齋衊衊鹹(糧顧壓淵鬱積繭簾鏇獵) = 艱鑰窪膚積廠蓋餘襯製 鏇艱窪壓鏇觸鏇壓齋獵 (醖築鹽齋築壓鹹廠鹹遞 ) 更多 | 积极 | 2023-12-02 | |||
临床2期 | 10 | 遞鬱觸願壓壓蓋觸鏇壓(壓糧範鏇衊獵選淵夢夢) = 壓網鹹鏇鹽膚醖築壓窪 憲齋製餘餘蓋遞簾鏇餘 (築顧糧遞廠糧齋醖餘顧 ) 更多 | 积极 | 2023-10-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用